TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00068601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Part of planned chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Part of planned chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given subcutaneously
Study: NCT01061671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 40 mgms of simvastatin daily
Study: NCT03228433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-418
Description: TAK-418 Capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-418 Placebo
Description: TAK-418 placebo-matching capsules.
Study: NCT01061671

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo pill daily
Study: NCT03320746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polar Loop 2 activity tracker
Description: The participants were instructed to aim to reach the daily activity goal, initially set at stage 1 as per the goals set by the trackers' manufacturer. The daily activity goal was based on user's typical daily activities, gender and age. The stage 1 daily activity goal corresponded to \~1h/day of jogging or \~2h/day of walking or \~7h/day household activities or a combination of these activities. The tracker gave an inactivity alert as a vibration and text it's time to move on the screen of the tracker if the user has been still for 55 minutes.
Study: NCT02529839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation
Description: IMMUNOABLATIVE NONMYELOABLATIVE AUTOLOGOUS BONE MARROW TRANSPLANTATION on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2 on days -6 through -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50mg/kg on days -5 through -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 3mg on day -3, 9mg on day -2, 12 mg on day -1
Study: NCT03268993

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Avmacol
Description: Avmacol is a dietary supplement available over the counter
Study: NCT02717520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EQUIA Forte and Tetric EvoCeram
Description: GC cavity conditioner (20% polyacrylic acid) will be applied for 10 sec, rinsed and the cavity will be dried with a cotton pellet. EQUIA Forte will be prepared according to the manufacturer instructions, applied in bulk and compacted with a condenser. The self-curing restoration will be finished after hardening, approximately 2 min 30 sec after the start of the capsule mixing, using Arkansas stones under water cooling. EQUIA Forte Coat will be applied to the surfaces and light cured with D-light for 20 sec.~Enamel will be etched with 37% orthophosphoric acid for 10 sec. After the acid gel removal, the cavity will be carefully dried. The adhesive (Adhese 2, Ivoclar Vivadent) will be applied and light cured with D-light (1200 mW/cm2, slow mode) for 10 sec. The composite resin will be placed with an incremental technique (2 mm layers), and light-cured with D-light (20 sec). Restorations will be finished with fine diamond and carbide burs in slow and high-speed hand-piece and polished.
Study: NCT03949530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDL-2965 Oral Capsule
Description: Investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT02489162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyotonPRO
Description: MyotonPRO measurements of the biomechanical properties of facial mimic muscles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyotonPRO
Description: MyotonPRO measurements of the biomechanical properties of facial mimic muscles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive electromyography (EMG)
Description: Gold standard technique for measuring muscle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive electromyography (EMG)
Description: Gold standard technique for measuring muscle
Study: NCT04119544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
Study: NCT04948801

Intervention type: DRUG
Intervention: Epclusa (sofosbuvir and velpatasvir)
Description: Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
Study: NCT05270876

Intervention type: DEVICE
Group type: OTHER
Intervention: Cochlear Implant and sound processor device fitting paradigm or diagnostic/measurement technique
Description: The investigational device will be a new device fitting paradigm or diagnostic/measurement technique implemented for use with the commercially available sound processor and implant.
Study: NCT01911351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
Study: NCT02793661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenalGuard
Description: Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Hydration protocol following ESC Guidelines 2014
Study: NCT03099473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular electroacupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
Study: NCT01101451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo radiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04948801

Intervention type: DRUG
Intervention: Epclusa (sofosbuvir and velpatasvir)
Description: Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.

Intervention type: DRUG
Intervention: Epclusa (sofosbuvir and velpatasvir)
Description: Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
Study: NCT00262301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human C1 inhibitor
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study: NCT01101451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03246607

Intervention type: DEVICE
Intervention: MicroEye & ContinuMon
Description: Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter.
Study: NCT00002593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV as described in Arm Description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV as described in Arm Description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV as described in Arm description.
Study: NCT04290013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norethisterone acetate
Description: norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid tablets
Description: tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.
Study: NCT02058875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoral®
Study: NCT00002593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levamisole hydrochloride
Description: Given as described in arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levamisole hydrochloride
Description: Given as described in arm description
Study: NCT02058875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cellcept®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study: NCT01823133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin only
Description: gemigliptin 50mg qd on day 1\~7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin only
Description: rosuvastatin 20mg qd on day 1\~7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin and rosuvastatin
Description: gemigliptin 50mg, rosuvastatin 20mg qd on day 1\~7
Study: NCT00677391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibutramine
Description: Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, once daily
Study: NCT03565315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB095-00-AB (10E8VLS)
Description: 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB095-00-AB (10E8VLS)
Description: 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB095-00-AB (10E8VLS)
Description: 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB095-00-AB (10E8VLS)
Description: 10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB (VRC07-523LS)
Description: VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB (VRC07-523LS)
Description: VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
Study: NCT03950427

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Videogame-based physical activity
Description: videogame-based physical activity

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: sedentary videogame
Description: sedentary videogame

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: Bupropion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling
Description: Counseling for smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Counseling for smoking cessation
Study: NCT04519931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress ball
Description: The stress ball is a toy, usually no larger than 7 cm. It is used to relieve stress and muscle tension. Stress ball is one of the cognitive and behavioral therapy methods used in pain control. Stress ball is used as a method of diverting attention during painful procedures. It appears to reduce pain and anxiety.
Study: NCT03648710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Community Health Worker
Description: Participants will be communicating with their CHWs on a weekly basis, which is consistent with other successful community health worker protocols with published efficacy. Community Health Workers will be peers with sickle cell disease, who have successfully transitioned and are under 30 years of age.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health
Description: A mobile health application created as a resource for young adults transitioning.
Study: NCT02169310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: There is no study intervention for Experiment 1. The study intervention for Experiment 2 is tDCS. tDCS is a non-invasive brain stimulation technique that uses electrodes attached to the scalp to deliver very low intensity direct current to the brain. This intervention has been demonstrated to result in neuromodulatory effects.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: There is no study intervention for Experiment 1. The study intervention for Experiment 2 is tDCS. tDCS is a non-invasive brain stimulation technique that uses electrodes attached to the scalp to deliver very low intensity direct current to the brain. This intervention has been demonstrated to result in neuromodulatory effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] Raclopride
Description: \[11C\] Raclopride is administered under an IND 054135. This IND is sponsored by the NIH Clinical Center and \[11C\] Raclopride is dispensed by the NIH PET Department. Quality Assurance for Radioactive Drug: \[11C\] Raclopride, is assayed for radiochemical purity under the supervision of the NIH PET Department prior to dispensing the drug for administration. Given that IND PET drugs manufactured at the NIH PET Department are used in a single site and that there is no intent for their commercialization, submission of IBs has not been required by FDA for any of the NIH Office of Research Support and Compliance-sponsored IND applications.
Study: NCT00752414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376 (Levofloxacin solution for Inhalation)
Description: Daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same frequency as MP-376
Study: NCT05121961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacroiliac intra-articular injection
Description: CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacroiliac intra-articular injection
Description: CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint
Study: NCT00444106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-mefloquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atovaquone-proguanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Study: NCT02115113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
Study: NCT02059421

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: - Therapy session administered by a clinical psychologist using web-based video conferencing software.~Therapy sessions will include:~* Sleep restriction therapy~* Stimulus control instructions~* Sleep hygiene education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Johrei therapy
Description: * Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.~* Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.~* Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.~* Therapy will be administered without physical contact.~* During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient.
Study: NCT02115113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
Study: NCT03023345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave trans rectal focal treatment
Description: Microwave trans-rectal ablation of the prostatic index tumor using MRI-transrectal ultrasound image registration
Study: NCT00011583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy
Description: 1 hour/day of mechanically-assisted upper limb therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional therapy
Description: 1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
Study: NCT02366325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO-018B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO-018B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO-018B
Study: NCT02606630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-555
Description: ABT-555 will be administered on Visit 4 in Part 2 only
Study: NCT03668964

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B2
Description: One capsule of 75 mg Vitamin B2 once a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: One capsule of 500 mg Vitamin C once a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B2 + C
Description: One capsule of of 75 mg Vitamin B2 plus 500 mg Vitamin C once a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: One capsule of 250 µg Vitamin A once a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: One capsule of 60 µg Vitamin D3 once a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: One capsule of 100 mg Vitamin E once a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of 575 mg microcrystalline cellulose once a day for 4 weeks
Study: NCT01625234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I: X-396 (ensartinib)
Description: Oral, ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: X-396 (ensartinib)
Description: Expanded Cohort
Study: NCT00566072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instructions and coaching
Description: instructions and coaching or no intervention on the use and intake of ganciclovir
Study: NCT02550015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Uphill treadmill walking

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: General information
Description: Standard care
Study: NCT02789852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthosis
Description: use orthosis